<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04715425</url>
  </required_header>
  <id_info>
    <org_study_id>NL63978.018.18</org_study_id>
    <nct_id>NCT04715425</nct_id>
  </id_info>
  <brief_title>Thoracoscopic Surgical Versus Catheter Ablation Approaches for Primary Treatment of Persistent Atrial Fibrillation</brief_title>
  <acronym>APPROACH AF</acronym>
  <official_title>Thoracoscopic Surgical Versus Catheter Ablation Approaches for Primary Treatment of Persistent Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rationale: Atrial fibrillation (AF) is a highly prevalent cardiac arrhythmia. AF is&#xD;
      classified as paroxysmal or persistent AF, based on the duration and persistency of the&#xD;
      arrhythmia. Despite state-of-the-art pharmacological therapies targeting the ventricular rate&#xD;
      or aiming to restore sinus rhythm, many patients with persistent AF stay symptomatic.&#xD;
      Catheter ablation, endocardial pulmonary vein isolation (PVI) in particular, is the most&#xD;
      commonly applied approach to treat drug refractory persistent AF, but particularly in this&#xD;
      patient group results are modest. Alternatively, the PVs can be approached epicardially by&#xD;
      thoracoscopic surgery to isolate the PVs. This approach is more efficacious, at the cost of a&#xD;
      more invasive procedure and longer hospital stay. However, no studies have been conducted&#xD;
      comparing catheter with thoracoscopic ablation in patients with persistent AF as a primary&#xD;
      invasive procedure after failing treatment with anti-arrhythmic medication.&#xD;
&#xD;
      Objective: This current study aims to assess a patient specific therapy plan for patients&#xD;
      with persistent AF by randomizing thoracoscopic versus catheter ablation for PVI without&#xD;
      adjuvant substrate ablation in those patients.&#xD;
&#xD;
      Study design: This is a prospective, non-blinded randomized multicenter study. Subjects will&#xD;
      be randomized (1:1) to one of the two study-arms (thoracoscopic surgical or catheter PVI).&#xD;
      The follow-up will last 5 years, with heart rhythm monitoring at three and six months, one&#xD;
      year and yearly in the following years. In case AF recurs during the first year, the subject&#xD;
      will receive the treatment of the otherother arm, or according to patient choice or clinical&#xD;
      routine.&#xD;
&#xD;
      Study population: Patients with an indication for invasive treatment of persistent AF.&#xD;
&#xD;
      Intervention: Thoracoscopic surgical or catheter PVI without additional lesions.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 25, 2019</start_date>
  <completion_date type="Anticipated">September 2028</completion_date>
  <primary_completion_date type="Anticipated">September 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Freedom of AF, defined as absence of any atrial tachyarrhythmia</measure>
    <time_frame>Up until 72 patients experienced AF recurrence</time_frame>
    <description>The primary endpoint of the study is freedom of AF, defined as absence of any atrial tachyarrhythmia without the use of antiarrhythmic drugs once a total number of 72 patients with AF recurrences after a single procedure have been reached. This is an event based endpoint. Freedom of atrial tachyarrhythmia is defined as the absence of documentation of episodes of atrial tachyarrhythmia lasting more than 30 seconds on Holter recordings during follow-up and/or on ECGs recorded outside the scope of the study.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>One year freedom of AF</measure>
    <time_frame>1 year of follow-up</time_frame>
    <description>Freedom of arrhythmia with or without AAD after a single procedure after one year</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom of AF after two procedures</measure>
    <time_frame>1 year of follow-up after the second procedure</time_frame>
    <description>Freedom of arrhythmia after 12 months with or without AAD after both procedures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long term freedom of AF</measure>
    <time_frame>5 years of follow-up</time_frame>
    <description>- Freedom of arrhythmia after 5 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost-effectiveness</measure>
    <time_frame>1 year of follow-up</time_frame>
    <description>- Cost-effectiveness of both procedures in isolation, and the combination of both procedures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>5 years of follow-up</time_frame>
    <description>Quality of life as determineed by AFEQT questionnaire</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">170</enrollment>
  <condition>Atrial Fibrillation, Persistent</condition>
  <arm_group>
    <arm_group_label>Thoracoscopic ablation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Thoracoscopic ablation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Catheter ablation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Catheter ablation</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Thoracoscopic pulmonary vein isolation without additional lesion + left atrial appendage exclusion/amputation</intervention_name>
    <description>Bilateral pulmonary vein isolation using radiofrequency energy</description>
    <arm_group_label>Thoracoscopic ablation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Catheter pulmonary vein isolation without additional lesions</intervention_name>
    <description>Bilateral pulmonary vein isolation using radiofrequency energy</description>
    <arm_group_label>Catheter ablation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age is between 18 and 80 years&#xD;
&#xD;
          -  Persistent AF as defined following the ESC 2016 Guidelines, evidenced by 1) ongoing AF&#xD;
             on the ECG or 2) documentation of AF necessitating cardioversion.&#xD;
&#xD;
          -  AF documented by ECG or Holter &lt; 1 year ago.&#xD;
&#xD;
          -  At least one class I or III anti-arrhythmic drug in standard dosage has failed or is&#xD;
             not tolerated.&#xD;
&#xD;
          -  Left atrial volume index ≤ 45 ml/m2&#xD;
&#xD;
          -  Legally competent and willing to sign the informed consent.&#xD;
&#xD;
          -  Willing and able to adhere to the follow-up visit protocol.&#xD;
&#xD;
          -  Life expectancy of at least 2 years.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior intervention (catheter ablation or minimally-invasive thoracoscopic ablation)&#xD;
             for AF.&#xD;
&#xD;
          -  AF is secondary to electrolyte imbalance, thyroid disease or other reversible or&#xD;
             non-cardiovascular causes.&#xD;
&#xD;
          -  Documentation of CTI dependent atrial flutter&#xD;
&#xD;
          -  Valvular AF&#xD;
&#xD;
          -  Paroxysmal AF&#xD;
&#xD;
          -  Long standing Persistent AF, defined as AF continuously present for longer than 1&#xD;
             year.&#xD;
&#xD;
          -  Body mass index &gt;35kg/m2&#xD;
&#xD;
          -  NYHA class IV heart failure symptoms or left ventricular ejection fraction &lt;35%.&#xD;
&#xD;
          -  NYHA class III heart failure symptoms, unless caused or aggravated by AF.&#xD;
&#xD;
          -  Myocardial infarction within the preceding 2 months.&#xD;
&#xD;
          -  Active infection or sepsis (as evidenced by increased white blood cell count, elevated&#xD;
             CRP level or fever &gt;38,5 °C).&#xD;
&#xD;
          -  Known and documented carotid stenosis &gt; 80%&#xD;
&#xD;
          -  Planned cardiac surgery for other purposes than AF.&#xD;
&#xD;
          -  Pregnancy or child bearing potential without adequate anticonception.&#xD;
&#xD;
          -  Requirement of anti-arrhythmic drugs for ventricular arrhythmias.&#xD;
&#xD;
          -  Presence of intracardiac mass or thrombus (discovery of any thrombus or intracardiac&#xD;
             mass after signing of the informed consent will result in withdrawal of the subject&#xD;
             from the study)&#xD;
&#xD;
          -  Co-morbid condition that possesses undue risk of general anesthesia or port access&#xD;
             cardiac surgery (in the opinion of the operator).&#xD;
&#xD;
          -  History of previous radiation therapy on the thorax&#xD;
&#xD;
          -  Circumstances that prevent follow-up&#xD;
&#xD;
          -  No vascular access for catheterization.&#xD;
&#xD;
          -  History of previous thoracotomy.&#xD;
&#xD;
          -  Factors precluding transseptal puncture for catheterization.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>J.R. de Groot, MD PhD</last_name>
    <phone>0205699111</phone>
    <email>EP-research@amsterdamumc.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>Amsterdam University Medical Center location AMC</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Maastricht UMC+</name>
      <address>
        <city>Maastricht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>St. Antonius Ziekenhuis Nieuwegein</name>
      <address>
        <city>Nieuwegein</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 13, 2021</study_first_submitted>
  <study_first_submitted_qc>January 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 20, 2021</study_first_posted>
  <last_update_submitted>January 18, 2021</last_update_submitted>
  <last_update_submitted_qc>January 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</investigator_affiliation>
    <investigator_full_name>J.R. de Groot</investigator_full_name>
    <investigator_title>prof. dr. J.R. de Groot</investigator_title>
  </responsible_party>
  <keyword>Catheter ablation</keyword>
  <keyword>Thoracoscopic ablation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

